FRA:MRK - Merck KGaA Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
€96.08 +0.08 (+0.08 %)
(As of 04/24/2019 02:04 PM ET)
Previous Close€96.00
Today's Range€94.96 - €96.08
52-Week Range€76.60 - €115.00
Volume636,119 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in laboratories; and specialty chemicals and functional materials for use in consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company also has collaboration with the Solvias to offer the PyroMAT system, a MAT kit for pyrogen detection; Immutep Limited; Leap Therapeutics, Inc.; and Personal Genome Diagnostics Inc. In addition, MERCK Kommanditgesellschaft auf Aktien has a collaboration with Daiichi Sankyo Company, Limited to evaluate the combination of DS-8201, an investigational HER2 targeting antibody drug conjugate; and a strategic alliance with genOway S.A. to develop CRISPR/Cas9-related products and solutions, as well as with GSK to develop and commercialize M7824, which is in Phase II trial for treating patients with PD-L1 expressing non-small cell lung cancer. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-6151-720

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Merck KGaA (FRA:MRK) Frequently Asked Questions

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What price target have analysts set for MRK?

21 brokers have issued twelve-month price targets for Merck KGaA's shares. Their forecasts range from €82.00 to €115.00. On average, they expect Merck KGaA's share price to reach €101.15 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price. View Analyst Price Targets for Merck KGaA.

What is the consensus analysts' recommendation for Merck KGaA?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 1 sell rating, 15 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

News stories about MRK stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck KGaA earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the healthcare company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of Merck KGaA's key competitors?

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include Micron Technology (MU), Cisco Systems (CSCO), NVIDIA (NVDA), QUALCOMM (QCOM), Boeing (BA), HDFC Bank (HDB), Netflix (NFLX), Starbucks (SBUX), Bank of America (BAC) and IBM (IBM).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
  • Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
  • Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
  • Ms. Belén Garijo López, CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €96.08.

What is Merck KGaA's official website?

The official website for Merck KGaA is https://www.merckgroup.com/.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.


MarketBeat Community Rating for Merck KGaA (FRA MRK)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  753 (Vote Outperform)
Underperform Votes:  842 (Vote Underperform)
Total Votes:  1,595
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel